We all know why NW stock was hammered after 5/10/22. The good news is that the OS data was presented well, and it we well received and many doctors, scientist and professionals who all agree. Manufacturing, manufacturing is the key factor to receive qualifications for a GMP and followed by the MIA/MA. The good news is that NWBO and its manufacturing partners are focusing on advanced automated manufacturing process which the Regulators respect and encourage prior to their approvals. Most investors do not have the technical insights regarding manufacturing process and the importance it has regarding regulatory approvals. Fortunately, there are a handful of individuals who strive to help investors understand the details and help inform them accordingly. Looking forward to approvals based on the fact that the OS data is in fact valid and will help both nGBM and rGBM brain cancer patients soon.
Market Data 
Markets 
AI
